Spectrum Pharma says ‘lucanthone’ could treat lung cancer
Biopharmaceutical company Spectrum Pharmaceuticals, Inc., (Nasdaq:SPPI) said this morning that preclinical data on lucanthone suggest the orally administered small molecule inhibitor of DNA repair could potentially be used for the treatment of lung cancer.
Shares gained 7.6%, or $0.19, to $2.69 at 10 a.m. ET. For detailed price information and recent news stories about Spectrum Pharmaceuticals, click SPPI.
About the Author
Reporter Jennifer Schonberger is based in SmallCapInvestor.com's Washington, D.C. bureau.
Read More
(click a star)
Enter comment: